Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial

Author:

Krucoff Mitchell,Spirito Alessandro,Baber Usman,Sartori Samantha,Angiolillo Dominick J.,Briguori Carlo,Cohen David J.,Collier Timothy,Dangas George,Dudek Dariusz,Escaned Javier,Gibson C. Michael,Han Ya-Ling,Huber Kurt,Kastrati Adnan,Kaul Upendra,Kornowski Ran,Kunadian Vijay,Vogel Birgit,Mehta Shamir R.,Moliterno David,Sardella Gennaro,Shlofmitz Richard A.,Sharma Samin,Steg Philippe Gabriel,Pocock Stuart,Mehran RoxanaORCID

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Reference32 articles.

1. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Lawton;Circulation,2022

2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

3. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention;Généreux;J Am Coll Cardiol,2015

4. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention

5. Bleeding avoidance strategies in percutaneous coronary intervention;Capodanno;Nat Rev Cardiol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3